{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:59:35Z","timestamp":1776326375023,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by the Philadelphia (Ph) chromosome. After the introduction of imatinib mesylate (IM) in 2000, the natural history of the disease changed. Data on the treatment of CML with IM are from randomized clinical trials. Establishing whether these results can be reproduced or if caution is needed when extrapolating data to the general population with CML is essential.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To evaluate the molecular response (MR) in patients with chronic-phase CML (CML-CP) not included in clinical studies and correlate them with the responses obtained in clinical trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Between January 2007 and January 2017, 227 patients newly diagnosed with CML-CP treated with IM as first-line treatment were included. This study is an observational, retrospective, and single-center study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At a median follow-up time of 7.3 years, 60.3% of the 227 patients who started IM were still on IM. Early molecular response (EMR) at 3 and 6 months was achieved by 74.2% and 65%, respectively. The median time to a MMR was nine months. The MR4.0 and MR4.5 were 67.2% and 51.1%, respectively. The overall survival (OS), progression-free survival (PFS), and event-free survival (EFS) of the patients who exclusively used IM were 91%, 91%, and 85.1%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The results presented are similar to those described in prospective and randomized trials, demonstrating that the outcomes are reproducible in the real world. EMR at 3 and 6 months reflects better long-term responses, including higher rates of deeper molecular responses. Considering treatment costs, the absence of literature evidence of an impact on overall survival demonstrated by first-line second-generation tyrosine kinase inhibitors (TKIs), and the global OS of 85.8%, imatinib mesylate (IM) is still an excellent therapeutic option.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00277-023-05189-3","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T04:02:43Z","timestamp":1681358563000},"page":"1761-1771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response"],"prefix":"10.1007","volume":"102","author":[{"given":"Amanda Pifano Soares","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda Salles","family":"Seguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre Ramires Neder","family":"Abdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda Maria","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe Vieira Rodrigues","family":"Maciel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Nardinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Rodrigues","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Roberto Lancha","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milton Pifano Soares","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Magalhaes","family":"Rego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4751-1428","authenticated-orcid":false,"given":"Israel","family":"Bendit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"5189_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290\u2013293. https:\/\/doi.org\/10.1038\/243290a0","journal-title":"Nature"},{"key":"5189_CR2","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031\u20131037. https:\/\/doi.org\/10.1056\/NEJM200104053441401","journal-title":"N Engl J Med"},{"key":"5189_CR3","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"5189_CR4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H (2018) Chronic myeloid leukemia: 2018 update on diagnosis, therapy, and monitoring. Am J Hematol 93:442\u2013459. https:\/\/doi.org\/10.1002\/ajh.25011","journal-title":"Am J Hematol"},{"key":"5189_CR5","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/ajh.24887","volume":"92","author":"SL Goldberg","year":"2017","unstructured":"Goldberg SL, Cortes JE, Gambacorti-Passerini C et al (2017) First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol 92:1214\u20131223. https:\/\/doi.org\/10.1002\/ajh.24887","journal-title":"Am J Hematol"},{"key":"5189_CR6","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1080\/10428194.2017.1379074","volume":"59","author":"G Saglio","year":"2018","unstructured":"Saglio G, Jabbour E (2018) First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. Leuk Lymphoma 59:1523\u20131538. https:\/\/doi.org\/10.1080\/10428194.2017.1379074","journal-title":"Leuk Lymphoma"},{"key":"5189_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","volume":"14","author":"G Rosti","year":"2017","unstructured":"Rosti G, Castagnetti F, Gugliotta G, Baccarani M (2017) Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol 14:141\u2013154. https:\/\/doi.org\/10.1038\/nrclinonc.2016.139","journal-title":"Nat Rev Clin Oncol"},{"key":"5189_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s11899-018-0449-7","volume":"13","author":"JA Kennedy","year":"2018","unstructured":"Kennedy JA, Hobbs G (2018) Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making. Curr Hematol Malig Rep 13:202\u2013211. https:\/\/doi.org\/10.1007\/s11899-018-0449-7","journal-title":"Curr Hematol Malig Rep"},{"key":"5189_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1182\/asheducation-2018.1.161","volume":"2018","author":"S Claudiani","year":"2018","unstructured":"Claudiani S, Apperley JF (2018) The argument for using imatinib in CML. Hematology Am Soc Hematol Educ Program 2018:161\u2013167. https:\/\/doi.org\/10.1182\/asheducation-2018.1.161","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"5189_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.clml.2017.05.006","volume":"17","author":"M Danthala","year":"2017","unstructured":"Danthala M, Gundeti S, Kuruva SP et al (2017) Generic Imatinib in Chronic Myeloid Leukemia: Survival of the Cheapest. Clin Lymphoma Myeloma Leuk 17:457\u2013462. https:\/\/doi.org\/10.1016\/j.clml.2017.05.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5189_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000339696","volume":"128","author":"I Bendit","year":"2012","unstructured":"Bendit I, Sanabani SS, Conchon M et al (2012) Evaluation of long-term outcomes, cytogenetic and molecular responses with imatinib mesylate in early and late chronic-phase chronic myeloid leukemia: a report from a single institute. Acta Haematol 128:223\u2013232. https:\/\/doi.org\/10.1159\/000339696","journal-title":"Acta Haematol"},{"key":"5189_CR12","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884. https:\/\/doi.org\/10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"key":"5189_CR13","doi-asserted-by":"publisher","unstructured":"Campos MGV de, de Campos MGV, de Moraes Arantes A, et al (2010) Chronic myeloid leukemia: A disease of youth in Brazil. Leukem Res 34:542\u2013544. https:\/\/doi.org\/10.1016\/j.leukres.2009.09.008","DOI":"10.1016\/j.leukres.2009.09.008"},{"key":"5189_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","volume":"2017","author":"F-X Mahon","year":"2017","unstructured":"Mahon F-X (2017) Treatment-free remission in CML: who, how, and why? Hematol Am Soc Hematol Educ Program 2017:102\u2013109. https:\/\/doi.org\/10.1182\/asheducation-2017.1.102","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"5189_CR15","doi-asserted-by":"publisher","first-page":"e004266","DOI":"10.1136\/bmjopen-2013-004266","volume":"4","author":"AG Smith","year":"2014","unstructured":"Smith AG, Painter D, Howell DA et al (2014) Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open 4:e004266. https:\/\/doi.org\/10.1136\/bmjopen-2013-004266","journal-title":"BMJ Open"},{"key":"5189_CR16","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/14737159.2016.1227243","volume":"16","author":"CCS Yeung","year":"2016","unstructured":"Yeung CCS, Egan D, Radich JP (2016) Molecular monitoring of chronic myeloid leukemia: present and future. Expert Rev Mol Diagn 16:1083\u20131091. https:\/\/doi.org\/10.1080\/14737159.2016.1227243","journal-title":"Expert Rev Mol Diagn"},{"key":"5189_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/14737167.2017.1366858","volume":"17","author":"M Marchetti","year":"2017","unstructured":"Marchetti M (2017) Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review. Expert Rev Pharmacoecon Outcomes Res 17:469\u2013480. https:\/\/doi.org\/10.1080\/14737167.2017.1366858","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"5189_CR18","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118:3123\u20133127. https:\/\/doi.org\/10.1002\/cncr.26679","journal-title":"Cancer"},{"key":"5189_CR19","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, SAKK and the German CML Study Group, Lauseker M et al (2017) Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 31:2398\u20132406","journal-title":"Leukemia"},{"key":"5189_CR20","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM et al (2016) Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 34:2333\u20132340. https:\/\/doi.org\/10.1200\/JCO.2015.64.8899","journal-title":"J Clin Oncol"},{"key":"5189_CR21","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP et al (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30:1044\u20131054. https:\/\/doi.org\/10.1038\/leu.2016.5","journal-title":"Leukemia"},{"key":"5189_CR22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F et al (2017) Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 376:917\u2013927. https:\/\/doi.org\/10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"key":"5189_CR23","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S et al (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423\u20131432. https:\/\/doi.org\/10.1056\/NEJMoa030513","journal-title":"N Engl J Med"},{"key":"5189_CR24","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"TP Hughes","year":"2008","unstructured":"Hughes TP, Branford S, White DL et al (2008) Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg\/day of imatinib as initial therapy. Blood 112:3965\u20133973. https:\/\/doi.org\/10.1182\/blood-2008-06-161737","journal-title":"Blood"},{"key":"5189_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ajh.24247","volume":"91","author":"C Gambacorti-Passerini","year":"2016","unstructured":"Gambacorti-Passerini C, Aroldi A, Cordani N, Piazza R (2016) Chronic myeloid leukemia: Second-line drugs of choice. Am J Hematol 91:67\u201375. https:\/\/doi.org\/10.1002\/ajh.24247","journal-title":"Am J Hematol"},{"key":"5189_CR26","doi-asserted-by":"publisher","unstructured":"Walia A, Prasad V (2023) Is it time to reconsider molecular response milestones in chronic myeloid leukemia? Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.26867","DOI":"10.1002\/ajh.26867"},{"key":"5189_CR27","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M et al (1984) Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63:789\u2013799","journal-title":"Blood"},{"key":"5189_CR28","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V et al (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118:686\u2013692. https:\/\/doi.org\/10.1182\/blood-2010-12-319038","journal-title":"Blood"},{"key":"5189_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S et al (2016) Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 30:48\u201356. https:\/\/doi.org\/10.1038\/leu.2015.261","journal-title":"Leukemia"},{"key":"5189_CR30","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","volume":"16","author":"JP Radich","year":"2018","unstructured":"Radich JP, Deininger M, Abboud CN et al (2018) Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16:1108\u20131135. https:\/\/doi.org\/10.6004\/jnccn.2018.0071","journal-title":"J Natl Compr Canc Netw"}],"updated-by":[{"DOI":"10.1007\/s00277-023-05242-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05189-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05189-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05189-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T06:03:39Z","timestamp":1686549819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05189-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["5189"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05189-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00277-023-05242-1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"19 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00277-023-05242-1","URL":"https:\/\/doi.org\/10.1007\/s00277-023-05242-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The study was approved by the ethics committee of the Hospital das Cl\u00ednicas at Faculdade de Medicina of the Universidade de Sao Paulo in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Author APSF declares that she has no conflict of interest. Author FSS that she has no conflict of interest. Author ARNA has received a speaker honorarium from Novartis, Brazil. Author FMS that she has no conflict of interest. Author FVRM that he has no conflict of interest. LN that she has no conflict of interest. RRG that he has no conflict of interest. ARLR that he has no conflict of interest. MPSF that he has no conflict of interest. EMR that he has no conflict of interest. VR that he has no conflict of interest. IB that he has no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}